TheraRadar

Pharma Intelligence, Simplified

← Back
Data updated: Mar 10, 2026

Gilead Sciences

GILD
Infectious DiseaseOncologyImmunology
Biotech

Antiviral specialist with dominant HIV franchise (Biktarvy, Descovy) and hepatitis C cures. Expanding into oncology through acquisitions.

$28.4B
Revenue (2024)
$115.0B
Market Cap
-
Trials
33
Approved (2yr)

Key Drugs

ZYDELIG
idelalisib
Oncology
PI3Kδ 3 indications · 2014
SUNLENCA
lenacapavir sodium
1 indications · 2022
STRIBILD
cobicistat
1 indications · 2012
EPCLUSA
sofosbuvir
Infectious Disease
1 indications · 2016
HARVONI
ledipasvir
Infectious Disease
1 indications · 2014

Recent Activity

LIVDELZI 2026-01-30
Labeling
VEKLURY 2025-10-07
Labeling
VEKLURY 2025-08-22
Labeling
BIKTARVY 2025-07-30
Efficacy
DESCOVY 2025-06-20
Efficacy
DESCOVY 2025-06-20
Efficacy
TYBOST 2025-06-20
Efficacy
TYBOST 2025-06-20
Efficacy
YEZTUGO 2025-06-18
Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated
YEZTUGO 2025-06-18
Type 10 - New Indication Submitted as Distinct NDA - Not Consolidated
SEC Filings Pro
Loading...

Therapeutic Focus

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Infectious Disease 59%
16 drugs Phase 3: 50 Phase 2: 54 Phase 1: 23
Oncology 26%
1 drugs Phase 3: 21 Phase 2: 27 Phase 1: 46
Immunology 10%
2 drugs Phase 3: 6 Phase 2: 13 Phase 1: 8
Gastroenterology 3%
0 drugs Phase 3: 2 Phase 2: 5 Phase 1: 4
Respiratory 2%
2 drugs Phase 3: 1 Phase 2: 1

Pipeline Strength Pro

Loading...

Competitors Pro

Pfizer big-pharma
Oncology, Infectious Disease, Immunology, Gastroenterology
GSK big-pharma
Infectious Disease, Respiratory, Oncology, Immunology
Sanofi big-pharma
Oncology, Infectious Disease, Immunology, Respiratory
Bristol-Myers Squibb big-pharma
Oncology, Immunology, Gastroenterology, Infectious Disease
Novartis big-pharma
Oncology, Immunology, Respiratory